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Hyperkalaemia is a potentially life-threatening condition frequently 
encountered in hospitalised patients.[1,2] It is associated with increased 
inpatient and all-cause mortality.[3] Various causes for hyperkalaemia 
exist, which can be identified with relative ease. These include 
increased intake of potassium in the form of supplementation or 
iatrogenic administration, increased intracellular potassium release 
(e.g. rhabdomyolysis or haemolysis), and decreased excretion (e.g. 
in renal failure). Medication is arguably the most common cause 
of hyperkalaemia and can be implicated in 75% of cases. The 
most common medications include angiotensin-converting enzyme 
inhibitors (ACE-Is), angiotensin receptor blockers (ARBs), digoxin, 
spironolactone and non-steroidal anti-inflammatories.[1,4]
We have a very high burden of HIV in South Africa (SA). As a 
result there is an increased incidence of opportunistic infections 
such as Pneumocystis jirovecii pneumonia (PJP) and both acute and 
chronic kidney disease due to HIV-associated nephropathy.[5] Patients 
with PJP require high doses of trimethoprim-sulfamethoxazole, 
which may cause life-threatening complications in the context of 
kidney disease.
We report one such case, in which life-threatening hyperkalaemia 
developed after institution of high-dose trimethoprim-sulfa-
methoxazole (co-trimoxazole) for PJP.
Case report
A 50-year-old woman with refractory hyperkalaemia was referred 
to the Renal Unit at Groote Schuur Hospital, Cape Town, SA. She 
was a known epileptic and was HIV-positive, with a history of poor 
adherence to treatment. She had defaulted on her antiretroviral 
medication for the past 2 years. Her CD4+ T-lymphocyte count was 
6 cells/µL and her HIV viral load 456 362 copies/mL.
The patient was admitted to hospital with breakthrough seizures. 
After her seizures had been controlled, it was noted that she was 
dyspnoeic and hypoxic on room air, and it was reported that she had 
had respiratory symptoms during the preceding week. Her blood 
pressure on admission was 121/58 mmHg, her pulse rate 79 beats/
min and her temperature 35.7oC. Her arterial oxygen saturation 
was 65% on room air and increased to 97% on non-rebreather 
mask oxygen. Her kidney function was normal (serum creatinine 
77 µmol/L, urea 7.9 mmol/L, sodium 134 mmol/L and potassium 
4.8 mmol/L). A chest radiograph revealed bilateral ground-glass 
opacifications. Based on the radiological findings, hypoxaemia 
and severe immune compromise, a diagnosis of PJP was made. 
Trimethoprim-sulfamethoxazole 1 600 mg/320 mg 6-hourly and 
prednisone 40 mg/d was started. The possibility of aspiration 
pneumonia was a concern, and ceftriaxone 1 g/d and azithromycin 
500 mg/d were therefore also administered.
The patient responded well within the first week of her admission. 
By day 8 her creatinine had almost doubled, and by the 10th day 
her blood results were as follows: creatinine 309 µmol/L, urea 
38.4 mmol/L, sodium 136 mmol/L and potassium 8.8 mmol/L. 
Clinically she was dehydrated. After administration of intravenous 
saline, she passed approximately 600 mL of clear urine. She received 
calcium gluconate, and attempts to lower her serum potassium 
with intravenous dextrose and insulin were futile. Oral sodium 
polystyrene sulfonate was also administered without success, and she 
had emergency haemodialysis to correct her potassium.
In the interim, the trimethoprim-sulfamethoxazole was 
discontinued and clindamycin and primaquine were started 
once the results of glucose-6-phosphate dehydrogenase (G6PD) 
assay was known. G6PD deficiency is an X-linked disorder that 
renders erythrocytes vulnerable to oxidative stress and haemolysis. 
Primaquine, like all 8-aminoquinoline compounds, can result 
in severe haemolysis in individuals with G6PD deficiency, and 
screening for this enzyme defect is recommended before these 
medications are commenced.[6] During the following days, the 
patient’s condition improved rapidly. By 7 days after stopping 
trimethoprim-sulfamethoxazole, her renal function and potassium 
had returned to normal (creatinine 46 µmol/L, urea 7.3 mmol/L, 
sodium 136 mmol/L and potassium 3.8 mmol/L).
Discussion
The combination antibiotic trimethoprim-sulfamethoxazole can 
affect kidney function in various ways. Firstly (and the most 
familiar renal side-effect associated with sulphonamide antibiotics) 
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is acute interstitial nephritis.[7] Secondly, in rare cases sulphonamides 
can cause crystal nephropathy, especially in an acidic, low-flow 
environment. Characteristic birefringent crystals in a ‘shock-of-
wheat’ arrangement are observed on urine microscopy.[7] Thirdly, 
trimethoprim interferes with creatinine secretion in the proximal 
convoluted tubule. This results in increased serum creatinine 
without affecting the glomerular filtration rate (GFR). This effect 
should therefore not be considered to be due to acute kidney 
injury. [7] Lastly, trimethoprim results in natriuresis and antikaliuresis. 
Trimethoprim blocks the epithelial sodium channels (ENaCs) in the 
distal convoluted tubules and collecting ducts. This effect is similar to 
the effect seen with the potassium-sparing diuretic amiloride. Indeed, 
trimethoprim and amiloride are structurally similar.[7]
In our case, the sequence of events was probably development 
of prerenal failure due to the natriuretic effect of trimethoprim, 
resulting in further accumulation of trimethoprim and increasing the 
risk of hyperkalaemia.
A 2015 retrospective study described two significant risk factors 
for the development of hyperkalaemia with trimethoprim use, 
namely pre-existing renal impairment (estimated GFR (eGFR) 
<60 mL/min/1.73 m2) and concomitant use of an ACE-I/ARB. 
The odds ratios for hyperkalaemia with low-dose trimethoprim-
sulfamethoxazole in these conditions have been reported as 4.62 and 
3.96, respectively.[8] Advanced age is also a recognised risk factor, 
as is the use of higher doses of trimethoprim.[9] A 2014 review of 
nearly 40 000 patients aged >66 years on an ACE-I or ARB who had 
an unexplained sudden death within 14 days of receiving outpatient 
antibiotic prescriptions found an odds ratio for sudden death of 1.54 
in patients who received trimethoprim-sulfamethoxazole compared 
with those receiving amoxicillin. This translates to ~3 deaths per 
1  000 trimethoprim-sulfamethoxazole prescriptions within 14 days 
of receiving trimethoprim-sulfamethoxazole.[9]
Certain measures have been proposed to minimise the risk 
of hyperkalaemia. Firstly, all patients receiving trimethoprim-
sulfamethoxazole should have their doses adjusted according to their 
current renal function. The current recommendation is to give usual 
doses every 18 - 24 hours if the eGFR is 30 - 60 mL/min, and a half 
dose every 12 - 18 hours if the GFR is 15 - 30 mL/min. Furthermore, 
it is recommended to avoid the drug when the GFR is <15 mL/
min.[10] The second strategy is to increase the sodium load to the 
distal nephron with intravenous saline. This increases the substrate 
for the ENaCs and increases flow rates, thereby minimising the 
effect of trimethoprim. Thirdly, it has been proposed that urinary 
alkalinisation decreases the amount of protonated form of the drug, 
also decreasing its efficacy.[8]
Hyperkalaemia should be addressed appropriately according to 
the serum potassium level. When it is established that hyperkalaemia 
is secondary to trimethoprim, the offending drug (and others 
that might exacerbate the situation) must be discontinued with 
immediate effect. Perazella[9] suggested that it may be reinitiated, at 
the appropriately adjusted dose, once renal function has returned 
to normal. Nevertheless, it would be prudent to consider an 
alternative to trimethoprim-sulfamethoxazole. Where trimethoprim 
is contraindicated, a primaquine-clindamycin combination or 
atovaquone can be considered for PJP.[11]
Conclusions
Trimethoprim-sulfamethoxazole is a commonly used antibiotic. It 
has long been reported to cause at least mild hyperkalaemia, yet 
there have been numerous reports of life-threatening hyperkalaemia 
associated with its use. Certain risk factors for hyperkalaemia have 
been identified, namely advanced age, higher doses of trimethoprim, 
concomitant use of an ACE-I/ARB, and pre-existing renal impairment. 
Clinicians should be cognisant of these conditions before prescribing 
trimethoprim-sulfamethoxazole, and should measure potassium 
levels in high-risk patients. Hyperkalaemia should be managed 
aggressively regardless of its cause. If trimethoprim-sulfamethoxazole 
has been implicated, it should be stopped and possibly replaced with 
an alternative drug.
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